Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012 | Zendy

Andrea Farnham | Zendy; Christopher Zimmerman | Zendy; Vikki Papadouka | Zendy; Kevin J. Konty | Zendy; Jane R. Zucker | Zendy; Geetha Nattanmai | Zendy; Sherly Jose | Zendy; Jennifer B. Rosen | Zendy

Open Access

Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012

Author(s) -

Andrea Farnham,

Christopher Zimmerman,

Vikki Papadouka,

Kevin J. Konty,

Jane R. Zucker,

Geetha Nattanmai,

Sherly Jose,

Jennifer B. Rosen

Publication year - 2015

Publication title -

jama pediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.004

H-Index - 183

eISSN - 2168-6211

pISSN - 2168-6203

DOI - 10.1001/jamapediatrics.2015.0612

Subject(s) - medicine , pneumococcal conjugate vaccine , pediatrics , incidence (geometry) , pneumococcal disease , meningitis , population , serotype , pneumonia , epidemiology , bacteremia , vaccination , streptococcus pneumoniae , immunology , environmental health , antibiotics , physics , optics , microbiology and biotechnology , biology

Invasive pneumococcal disease (IPD) is a leading cause of pneumonia, meningitis, and bacteremia in children. In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine childhood immunization schedule. The PCV13 contains 6 serotypes not included in the previously recommended 7-valent pneumococcal conjugate vaccine, including serotype 19A, the predominant cause of IPD prior to the introduction of PCV13.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research